随着 FDA 计划从动物试验转向 AI，Charles River Laboratories 的股价暴跌 28%。 Charles River Laboratories' stock plunges 28% as FDA plans shift to AI from animal testing.

Charles River Laboraties的库存量下降28.13%至99.95美元,因为林业发展局宣布计划逐步停止动物试验,改用人工智能药物开发方法。 Charles River Laboratories' stock fell 28.13% to $99.95 after the FDA announced plans to phase out animal testing in favor of AI methods for drug development. 这一变化可能会降低成本和药物价格,但会给查尔斯河实验室带来负面影响,后者侧重于传统动物试验。 This change could reduce costs and drug prices but negatively impacts Charles River Laboratories, which focuses on traditional animal trials. 股票下跌与更广泛的市场下滑相一致,主要指数也大幅度下降。 The stock drop aligns with a broader market downturn, with major indices also falling significantly.